Helix BioMedix Inc. (OTCMKTS:HXBM – Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 204 shares, a growth of 240.0% from the August 15th total of 60 shares. Based on an average daily trading volume, of 280 shares, the short-interest ratio is presently 0.7 days. Currently, 0.1% of the shares of the company are sold short.
Helix BioMedix Price Performance
Shares of OTCMKTS HXBM remained flat at $6.00 during mid-day trading on Monday. The company had a trading volume of 400 shares, compared to its average volume of 317. The stock’s fifty day moving average price is $2.30 and its 200 day moving average price is $1.80. Helix BioMedix has a 52-week low of $1.00 and a 52-week high of $6.50.
Helix BioMedix Company Profile
Helix BioMedix, Inc (OTCMKTS: HXB M) is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic and supportive care products for cancer patients. The company’s research and development efforts center on leveraging the body’s innate immune system to enhance anti-tumor responses, with a pipeline that includes biologics designed to modulate immune checkpoints and activate phagocytic cells against tumor targets.
Operating from its headquarters in Cambridge, Massachusetts, Helix BioMedix applies proprietary discovery and screening platforms to identify and optimize lead candidates.
See Also
- Five stocks we like better than Helix BioMedix
- 3 European Banks That Could Win Big From ECB Rate Hikes
- SM Energy’s Civitas Merger Is Paying Off, But the Stock’s Run Raises the Bar
- Intel’s Price Hikes Could Put $120 Back in Play
- Blue-Chip Stocks Are Looking Anything But Boring With Dividends and Big 2026 Gains
Receive News & Ratings for Helix BioMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioMedix and related companies with MarketBeat.com's FREE daily email newsletter.
